METHODS FOR TREATING A PATIENT HAVING A DISEASE OR DISORDER, To treat a patient with autoimmune disease, TO NEUTRALIZE A TYPE 1 IFN INDUCIBLE PD MARKER EXPRESSION PROFILE OR IFNALFA IN A PATIENT, FOR MONITORING OR PROGNOSTICING A PATIENT'S AUTOIMMUNE DISEASE PROGRESS, TO MONITOR DISEASE PROGRESS OF A PATIENT RECEIVING TREATMENT WITH A THERAPEUTIC AGENT CONNECTING TO AND MODULATING IFNALFA'S ACTIVITY, TO IDENTIFY A PATIENT AS A CANDIDATE FOR A THERAPEUTIC AGENT CONNECTING AND MODULATING IFNALFA'S ACTIVITY, TO DIAGNOSE A PATIENT AS HAVING A DISTRESS ASSOCIATED WITH INCREASED IFNALFA LEVELS, TO IDENTIFY A CANDIDATE THERAPY FOR THE TREATMENT OF IFNALFA-MEDIATED DISORDERS AND TO DETECT IFN ACTIVITY IN A SAMPLE, Probe Set, AND, KIT

摘要

The method for identifying a patient as a candidate for a therapeutic agent that binds and modulates ifnalfa activity. The present invention encompasses ifn type 1 and ifnalfa-induced pd marker expression profiles, kits and methods for identifying such ifnfa profiles. ifnalfa-induced pd marker expression. ifn type 1 and ifna induced pd marker expression profiles can also be used, for example, in methods of treating patients having an ifn type 1 or ifnalfa-mediated disorder, methods of monitoring disease progression in patients receiving treatment with a therapeutic agent that binds to and modulates ifna activity, Identification of patients as candidates for treatment-binding and neutralizing ifna activity and in diagnosing or providing a prognosis for patients having ifnalfa-induced disorders.